Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report for Connecticut by County

Pancreas (Late Stage^), 2017-2021

All Races (includes Hispanic), Female, All Ages

Sorted by Name

Explanation of Column Headers

Objective - The objective of *** is from the Healthy People 2020 project done by the Centers for Disease Control and Prevention.

Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Percent of Cases with Late Stage - This is the number of late stages cases compared to the number of cases for all stages.


Other Notes


Line by Line Interpretation of the Report


Connecticut3


US (SEER+NPCR)1


Windham County7


Tolland County7


New London County7


New Haven County7


Middlesex County7


Litchfield County7


Hartford County7


Fairfield County7




Notes:
Created by statecancerprofiles.cancer.gov on 12/04/2024 12:25 pm.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Φ Rural-Urban Continuum Codes provided by the USDA.
1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
3 Source: SEER November 2023 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
7 Source: SEER November 2023 submission.

Note: This website still uses Connecticut counties instead of planning regions for consistency of geographies across data topics. If/when all data sources have new planning regions, then this website will switch to using them. 2013 Rural-Urban Continuum Codes will be used for Connecticut counties.

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.